论文部分内容阅读
冠状动脉慢性完全闭塞病变(CTO)在冠心病人群患病率高,介入治疗能改善左室功能、缓解症状、提高生活质量、改善长期生存;但存在高再狭窄、再闭塞风险.金属支架较冠状动脉腔内成型术明显改观,仍有难以接受的高再狭窄、再闭塞率.第一代药物洗脱支架将再狭窄、再闭塞风险降低至可接受范围同时,改善主要心血管不良事件亦有明显优势;第二代药物洗脱支架取得更近一步的优势.生物可吸收支架治疗CTO降低再狭窄、再闭塞风险,同时骨架与涂层能被完全吸收而让其获得独特优势;药物球囊治疗CTO能获得良好耐受,无支架介入治疗CTO成为可能.“,”Coronary artery chronic total occlusion (CTO) lesions have a high prevalence in patients with coronary heart disease.The patients with CTO treated by intervention may get better left ventricular function ,better quality of life ,surviving from symptoms and long-term survival.However there is high risk of restenosis and reocclusion.Metal stents significantly improved over coronary percutaneous transluminal coronary angioplasty but still had unacceptably high restenosis and reocclusion rates .The first-generation drug-eluting stents reduced the risk of restenosis and reocclusion to acceptable scope , and had obvious advantages in improving major cardiovascular adverse events simutaneously;and the second-generation drug-eluting stents has taken a one-step further.The non-degradable polymer coating of drug-eluting stents may be associated with late or very late in-stent thrombosis,and other novel drug scaffolds such as biodegradable polymer stents attempt to be applied to CTO lesions.Bioresorbable stents for the treatment of CTO lesions with low restenosis and occlusion risk is safety and effective,while the skeleton and the coating can be completely absorbed to give it a unique advantage .Drug-coated balloon for intervention CTO lesions without stent may be well tolerated.